Recent News

• 12.05.2025 - Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
• 12.04.2025 - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 12.03.2025 - Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
• 11.25.2025 - Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
• 11.06.2025 - Xenon to Present at Upcoming Investor Conferences
• 11.03.2025 - Xenon Reports Third Quarter 2025 Financial Results & Business Update
• 10.27.2025 - Xenon to Report Q3 2025 Financial Results on November 3, 2025
• 10.16.2025 - Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

Recent Filings

• 12.05.2025 - 144 Report of proposed sale of securities
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 12.01.2025 - 144 Report of proposed sale of securities
• 12.01.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.03.2025 - 8-K Current report
• 11.03.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2025 - EX-99.1 EX-99.1
• 10.17.2025 - 4 Statement of changes in beneficial ownership of securities